Our results demonstrated that ME ameliorated inflammation-associated intestinal fibrosis with TGF-β1/SMADs pathway inhibition through overexpressing Nrf2 in chronic DSS colitis and human intestinal fibroblasts. Here, TGFB1 is linked to fibrosis.